ClinicalTrials.Veeva
Menu

Find clinical trials for Lung Cancer in Portland, OR

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Non-Small-Cell Lung Carcinoma
Small Cell Lung Carcinoma
Cancer
Colorectal Cancer
Neoplasm Metastasis
Breast Cancer
Squamous Cell Carcinoma of Head and Neck

Lung Cancer trials near Portland, OR, USA:

Autologous LN-145 in Patients With Metastatic Non-Small-Cell Lung Cancer

a prospective, open-label, multi-cohort, non-randomized, multicenter phase 2 study evaluating LN-145 in patients with metastatic non-small-cell lung...

Enrolling
Metastatic Non Small Cell Lung Cancer
Biological: LN-145

Phase 2

Iovance Biotherapeutics

Portland, Oregon, United States and 72 other locations

Recently updated

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

This study will enroll adult participants with early-stage (stage II-IIIB) non-small cell lung cancer (NSCLC) for whom surgery is p...

Active, not recruiting
Non Small Cell Lung Cancer
NSCLC
Drug: REGN10597
Drug: Marlotamig

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Portland, Oregon, United States and 46 other locations

HERTHENA-Lung01: Patritumab Deruxtecan in Subjects With Metastatic or Locally Advanced EGFR-mutated Non-Small Cell Lung Cancer

This study is designed to evaluate the antitumor activity of patritumab deruxtecan in participants with metastatic or locally advanced NSCLC with an...

Active, not recruiting
Non-Small Cell Lung Cancer Metastatic
Non-Small Cell Lung Cancer With Mutation in Epidermal Growth Factor Receptor
Drug: Patritumab Deruxtecan (Fixed dose)
Drug: Patritumab Deruxtecan (Up-Titration)

Phase 2

Daiichi Sankyo
Daiichi Sankyo

Portland, Oregon, United States and 123 other locations

A Study to Investigate Ubamatamab With and Without Marlotamig (REGN7075) in Adult Participants With Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

This study will evaluate two study drugs called ubamatamab and marlotamig, to see if they can help treat advanced or metastatic Non-Small Cell Lung...

Enrolling
Carcinoma Non Small Cell Lung
Advanced Non Small Cell Lung Cancer
Drug: Sarilumab
Drug: Marlotamig

Phase 2

Regeneron Pharmaceuticals
Regeneron Pharmaceuticals

Portland, Oregon, United States and 17 other locations

A Study of I-DXd in Combination With Atezolizumab With or Without Carboplatin as First-Line Induction or Maintenance in Subjects With Extensive Stage-Small Cell Lung Cancer (IDeate-Lung03)

in combination with immune checkpoint inhibitor (ICI) atezolizumab with or without carboplatin in participants with extensive stage-small cell lung...

Enrolling
Extensive Stage-small Cell Lung Cancer
Drug: Carboplatin
Drug: Ifinatamab deruxtecan

Phase 1, Phase 2

Daiichi Sankyo
Daiichi Sankyo

Vancouver, Washington, United States and 59 other locations

A Study of Ifinatamab Deruxtecan Versus Treatment of Physician's Choice in Subjects With Relapsed Small Cell Lung Cancer (IDeate-Lung02)

This study is designed to compare the efficacy and safety of I-DXd with treatment of physician's choice in participants with relapsed small cell lung...

Enrolling
Small Cell Lung Cancer
Drug: Amrubicin
Drug: Lurbinectedin

Phase 3

Daiichi Sankyo
Daiichi Sankyo

Portland, Oregon, United States and 233 other locations

Phase 2 Platform Study in Patients With Advanced Non-Small Lung Cancer Who Progressed on First-Line Osimertinib Therapy (ORCHARD)

Phase 2 Platform Study in Patients with Advanced Non-Small Lung Cancer who progressed on First-Line Osimertinib Therapy. This study...

Active, not recruiting
Non-Small Cell Lung Cancer
Drug: Cisplatin
Drug: Alectinib

Phase 2

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 46 other locations

A Study to Evaluate Adverse Events and Change in Disease Activity of Intravenous ABBV-706 Versus Standard of Care in Adult Participants With Relapsed/Refractory Small Cell Lung Cancer

Small cell lung cancer (SCLC) is characterized by aggressive and rapid growth and a tendency to develop early spread to distant sit...

Enrolling
Small Cell Lung Cancer
Drug: Topotecan
Drug: Lurbinectedin

Phase 3

AbbVie
AbbVie

Portland, Oregon, United States and 71 other locations

A Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Participants With Previously Treated KRAS G12C-positive Advanced or Metastatic Non-Small Cell Lung Cancer (Krascendo 1)

KRAS G12C inhibitors (sotorasib or adagrasib) in participants with KRAS G12C-positive (KRAS G12C +) advanced or metastatic non-small cell lung...

Active, not recruiting
KRAS G12C Lung Cancer
Non-Small Cell Lung Cancer
Drug: Sotorasib
Drug: Divarasib

Phase 3

Roche
Roche

Portland, Oregon, United States and 156 other locations

Study of Durvalumab + Tremelimumab, Durvalumab, and Placebo in Limited Stage Small-Cell Lung Cancer in Patients Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)

This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as...

Active, not recruiting
Small Cell Lung Cancer
Drug: Durvalumab
Other: Placebo

Phase 3

AstraZeneca
AstraZeneca

Portland, Oregon, United States and 182 other locations

Clinical trials

Find clinical trialsTrials by location

Research sites

Find research sitesLearn about CTV for professionals

Resources

Contact CTV support

Legal

Privacy NoticeTerms
© Copyright 2026 Veeva Systems